Infertility is becoming a public health issue in Europe. In the EU, infertility affects approximately 25 million citizens . In worildwide, it is estimated that one out of six people experience some form of infertility during their reproductive lifespan. Europe is characterized by low fertility, postponed childbearing, increase in childlessness among younger generations. OvAge s.r.l. is a business start-up born from one of the best cutting-edge research of the University Magna Graecia of Catanzaro. Its mission is to improve women quality of life by bringing to the international market medical devices for the solution of gynaecological diseases. OvAge s.r.l. is the owner of a pioneering medical device-software able in quantifying women ovarian reserve (OR) by integrating clinical, biochemical and 3D- ultrasonographic data. This instrument, called OvAge®, is already developed as a patented mathematical algorithm. OvAge® combines complementary evaluations to give as a result explicitly the ovarian age of every woman, a ready-to-use information that is going to revolutionize the relationship of women with themselves, their life and with the Specialists in the field of Gynaecology